---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026668"
form_type: "8-K"
ticker: "CBLL"
cik: "0001861107"
company_name: "Ceribell, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:58:13.812916+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M

## Summary
- Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.
- FY2024 revenue $65.4M (+45%); net loss $40.5M ($3.39/share) vs $29.5M ($5.56/share) in 2023.
- Cash and equivalents $194.4M at Dec 31, 2024; active accounts 529; over 200,000 patients treated.
- FY2025 revenue guidance $81-85M, representing 24-30% growth over FY2024.
- Submitted 510(k) for pediatric Clarity algorithm; Sean Manni promoted to Chief Revenue Officer.

## SEC filing metadata
- accession: 0000950170-25-026668
- form_type: 8-K
- ticker: CBLL
- cik: 0001861107
- company_name: Ceribell, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861107/000095017025026668/0000950170-25-026668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861107/000095017025026668/cbll-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026668
- JSON: https://secwatch.observer/filing/0000950170-25-026668.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.